Plateaued on tirzepatide?
Your next step is here.

Retatrutide is a triple-agonist medication that activates three receptor pathways: GLP-1 (appetite control), GIP (fat metabolism), and glucagon (energy expenditure and fat oxidation). While semaglutide activates only GLP-1 and tirzepatide activates GLP-1 and GIP, retatrutide adds the glucagon pathway. In Phase 2 clinical trials, this triple mechanism produced up to 28.6% body weight loss over 48 weeks - significantly exceeding dual-agonist results. The glucagon component specifically increases basal metabolic rate and promotes direct fat burning, addressing the metabolic adaptation that causes plateaus with existing medications.

Retatrutide is currently an investigational medication. It completed a successful Phase 2 clinical trial (n=338) showing significant efficacy and is currently in Phase 3 trials. It has not yet received FDA approval. All treatment decisions at Linux Health are made by licensed physicians who evaluate each patient individually. Our physicians stay current with the latest clinical evidence and can discuss the regulatory status and available options during your consultation.

The triple-agonist escalation protocol is designed for patients who have been on tirzepatide (Zepbound or Mounjaro) for at least three months and have experienced a plateau in weight loss, are not reaching their goal weight, or have experienced diminishing results despite dose escalation. Candidates should have a BMI of 27 or higher and no contraindications to GLP-1 receptor agonist therapy. Your physician will conduct a thorough evaluation of your treatment history, current health status, and goals to determine if escalation is appropriate.

In clinical trials, patients on retatrutide began seeing significant additional weight loss within the first 12 weeks of treatment. The glucagon pathway activates relatively quickly, increasing energy expenditure and fat oxidation early in the treatment course. Most patients who had plateaued on dual-agonist therapy observed a resumption of weight loss within 4 to 8 weeks. Maximum results in the Phase 2 trial were observed at 48 weeks, with the highest dose group achieving 28.6% total body weight loss. Individual results vary based on dosing, adherence, diet, and activity levels.

The most common side effects observed in clinical trials were gastrointestinal - nausea, diarrhea, vomiting, and constipation - similar to other GLP-1 receptor agonist medications. These side effects were generally mild to moderate and decreased over time as patients adjusted to the medication. Because retatrutide includes a glucagon component, some patients may experience a slight increase in heart rate or mild elevation in blood sugar during initial titration. Your physician will use a gradual dose escalation protocol to minimize side effects and will monitor your response closely. If you have tolerated tirzepatide well, you may have an easier transition to retatrutide.

The advanced escalation protocol starts at $124.99 per month for the Essential plan, which includes the medication and standard physician oversight. The Preferred plan at $144.99 per month adds weekly physician access, metabolic monitoring, and priority dosing adjustments. The Premium plan at $179.99 per month provides a dedicated physician, advanced metabolic panels, personalized nutrition planning, and unlimited physician messaging. All plans include the cost of medication. Your initial consultation is free and carries no obligation. Many patients find the investment worthwhile given the significant additional weight loss achievable with triple-agonist therapy.